Magdi Elsallab, MD, PhD

Instructor @harvard | @marcelamaus lab | GMP process development | CAR-T enthusiast | Pushing innovations through bottlenecks

[Magdi Elsallab, MD, PhD @ElsallabMagdi]

🚨 Exciting News! 🚨
The largest analysis of cell and gene therapy clinical development success probabilities is here!

What we did:
- Analyzed 900+ cell and gene therapies and 2,500 clinical trials to build 1,900 development programs.

Read here
https://t.co/HVil02hc5x

[JAMA Internal Medicine @JAMAInternalMed]

Discrepancies in clinical trial evidence reported to the FDA and EMA for cell and gene therapies highlight the need for harmonization in regulatory submissions. https://t.co/fDVqOccC2Y

[Society of Hematologic Oncology (SOHO) @SocietyofHemOnc]

The Hospital Clínic de Barcelona & @MedicalCollege are rethinking how #CAR-T therapies are manufactured. Read our feature on the topic
https://t.co/wRKz0JHBSW

@niravshahmd @ElsallabMagdi Leticia Alserawan

[Harvard-MIT Center for Regulatory Science @HarvardMIT_CRS]

@HarvardMIT_CRS Director @ftbourgeois, former CRS fellow @ElsallabMagdi, and former visiting student Sandra Gillner, publish @JAMAInternalMed study comparing evidence submitted to the FDA and EMA for cell and gene therapies.

Find the full study here: https://t.co/dRSrhYXAmQ

[Magdi Elsallab, MD, PhD @ElsallabMagdi]

This project has been a passion of mine since my PhD days, and I’m grateful for the incredible support from the @HarvardMIT_CRS fellowship program, and Dr. Florence Bourgeois @ftbourgeois who made this work possible.

[Magdi Elsallab, MD, PhD @ElsallabMagdi]

🚨 Exciting News! 🚨
The largest analysis of cell and gene therapy clinical development success probabilities is here!

What we did:
- Analyzed 900+ cell and gene therapies and 2,500 clinical trials to build 1,900 development programs.

Read here
https://t.co/HVil02hc5x

[Magdi Elsallab, MD, PhD @ElsallabMagdi]

Why this matters:
This study provides critical insights into factors driving success in cell and gene therapy development, helping shape strategies for researchers, developers, and regulators.

[Josh Tycko @JoshTycko]

check out Eva Gottwein's new preprint carefully measuring the toxicity of some CRISPRa activation systems.

This is an issue today for functional genomics research and potentially for future therapeutics that use synthetic transcriptional activators
https://t.co/83i36wFaVw

[Dimitrios L. Wagner @dlwagner13]

Preprint alert 🚨

Up to 90% CAR knock-in rates in primary human T cells - without drug enhancers? 🧐

Single-stranded HDR templates with truncated Cas12a binding sequences improve knock-in efficiencies in primary human T cells

https://t.co/76xEoKTGsr

🧵👇

[Magdi Elsallab, MD, PhD @ElsallabMagdi]

@iselkholi @Cancer_Cell @DrDrAprilRose @JAguirreGhiso @JF_CoteLab Congrats Islam ��🏼

[Nature Reviews Drug Discovery @NatRevDrugDisc]

The FDA has approved the first telomerase inhibitor, imetelstat, to treat myelodysplastic syndromes following an epic journey for the drug, which has been tested in more than 20 trials over the past 20 years in various cancers. Find out more here https://t.co/w6a7pocLKX

[Magdi Elsallab, MD, PhD @ElsallabMagdi]

Great overview of the cellular immunotherapy landscape.

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Interested in cell therapies in oncology? A new landscape analysis from @CancerResearch Institute and @IQVIA_global discusses clinical research and real-world data on the use and implementation of this modality https://t.co/XxXAfrdVSg

[Magdi Elsallab, MD, PhD @ElsallabMagdi]

Happy to see our work on the cover of @BloodJournal! If you haven’t read it yet, check out our study analyzing FDA adverse event reports for second primary malignancies post-CAR T cells:
https://t.co/dAypSwAyHN

[Blood Journals Portfolio @BloodPortfolio]

The newest issue of Blood is now available.
https://t.co/bpwCZYKies
#hematology

[Patrick J. Hanley 🧬 @DrPHanley]

More momentum on the #POC manufacturing front. Enter, regional blood banks. @GalapagosGlobal @BCAbloodcenters https://t.co/JDGkmD9zDt

[Magdi Elsallab, MD, PhD @ElsallabMagdi]

@DrPHanley @GalapagosGlobal @BCAbloodcenters Very important step indeed!

[Dimitrios L. Wagner @dlwagner13]

🚀 Join Our Team at Baylor College of Medicine! 🧬

We’re looking for passionate technician to join our lab at @CAGTHouston. Help us develop innovative and accessible cell therapies for cancer and autoimmunity using genome editing.

Pls RT 🙏

https://t.co/hfwtEN8t6s

[Marco Ruella @MarcoRuella]

@carlhjune and I reviewed the current evidence on the potential risk of T-cell lymphoma after #CART immunotherapy. Now online @BCD_AACR !!! @PennMedicine @PennCancer https://t.co/HjF63i3qQ9

[Blood Cancers Today @Blood_Cancers]

What is the incidence of T-cell malignancies after CAR-T?

@ElsallabMagdi, of @MGHCancerCenter, and @EllithiMd, of @UNMC, stopped by BCT to discuss their FAERS database analysis on T-cell malignancies after CAR-T.

📺 Watch here: https://t.co/ldxb5l0koi

[Magdi Elsallab, MD, PhD @ElsallabMagdi]

@NatureBiotech This study would not have been possible without the great contributions and support of @MarcelaMaus and @ftbourgeois.

[Magdi Elsallab, MD, PhD @ElsallabMagdi]

Glad to extend further on the local manufacturing story of immune effector cells (IECs). Out now in @ASTCT_Journal. We surveyed 157 FACT-accredited facilities in the US for their readiness for local manufacturing. The bottom line: a two-stage approach. First, we can leverage academic Good Manufacturing Practice facilities for local manufacturing. Second, we support facilities for minimal manipulation to be ready for local manufacturing. How far are we? I would say not far, but we need to put in the work.

Read here https://t.co/Gnm1ocmnQ9

[Magdi Elsallab, MD, PhD @ElsallabMagdi]

If you haven't read our perspective in @NatureBiotech regarding the regulatory frameworks for local manufacturing of IECs, you can find it here https://t.co/m6R4nZl8HO